Evidence map›Paper›PMID 42426455›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Characterization of Circulating Tumor Cells and Other Rare Cells in Blood Using the RareCyte Platform.

Arturo B Ramirez, Jon Ladd, Erin G Bayer, Brock Bartels, Casey Helmicki, Rachel N Ponting, Daniel E Campton, Joshua J Nordberg, Eric P Kaldjian

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arturo B RamirezRareCyte Inc., Seattle, WA, USA. aramirez@rarecyte.com.
Jon LaddRareCyte Inc., Seattle, WA, USA.
Erin G BayerRareCyte Inc., Seattle, WA, USA.
Brock BartelsRareCyte Inc., Seattle, WA, USA.
Casey HelmickiRareCyte Inc., Seattle, WA, USA.
Rachel N PontingRareCyte Inc., Seattle, WA, USA.
Daniel E CamptonRareCyte Inc., Seattle, WA, USA.
Joshua J NordbergRareCyte Inc., Seattle, WA, USA.
Eric P KaldjianRareCyte Inc., Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare cell populations in blood are of high research and diagnostic interest. The RareCyte platform is an end-to-end technology solution from sample collection to fluorescence imaging-based detection and characterization of rare cells from whole blood samples. The benefits of the platform include ease of use, robust repeatability, automated staining using validated protocols and reagent kits, post-collection stability of blood samples, long-term storage of processed slide smears before testing, high-sensitivity detection of rare cells, dual-biomarker phenotypic characterization of rare cells, single rare cell isolation for molecular analysis, and flexibility to detect non-epithelial cells of interest in circulation. For this volume, we will focus on circulating tumor cells (CTCs) as exemplar rare cells for analysis.The workflow begins by collecting blood samples into AccuCyte

Indexed as

Cell SeparationNeoplastic Cells, CirculatingSingle-Cell AnalysisBiomarkers, TumorBlood Specimen CollectionHumansBiomarkers, TumorBiomarkerComprehensive analysisCTCDensity-based separationImmunofluorescent stainingLiquid biopsyPredictive markerPrognostic marker

Identifiers

PMID42426455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.